Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the currently recommended treatment for advanced EGFR mutation-positive non-small cell lung cancer (NSCLC). Acquired resistance inevitably develops, with the EGFR T790M mutation comprising approximately 55% of the mechanisms...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Bin-Chi, Griesing, Sebastian, Yang, James Chih-Hsin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878608/
https://www.ncbi.nlm.nih.gov/pubmed/31803256
http://dx.doi.org/10.1177/1758835919890286

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6878608/
https://www.ncbi.nlm.nih.gov/pubmed/31803256
http://dx.doi.org/10.1177/1758835919890286

Ejemplares similares